Indoco Remedies' Baddi plant gets EU GMP approval from Malta Medicines Authority
The certification follows an inspection conducted by the Malta Medicines Authority between January 29, 2026, and February 3, 2026
The certification follows an inspection conducted by the Malta Medicines Authority between January 29, 2026, and February 3, 2026
Darolutamide Tablets, 300 mg, had an estimated market size of US$ 3,155 million in the United States
The decision marks a significant expansion for Pfizer’s once-weekly injectable therapy
The once-daily oral therapy is the first and only tyrosine kinase 2 (TYK2) inhibitor approved in the European Union for this indication, marking a significant expansion of its immunology portfolio
Approval strengthens the company’s growing international anti-infective portfolio
Fresenius Kabi's approved generic therapy addresses acute symptomatic hypocalcemia and targets a US market valued at nearly $71 million
Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs
Approval expands Lupin’s specialty portfolio in the US market for treatment of urea cycle disorders
The US regulator conducted an inspection at the Amaliya manufacturing plant between April 20 and May 1, 2026
Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
The Puducherry facility, dedicated to Ibuprofen and its derivatives, is equipped with advanced infrastructure to serve both domestic and international markets
Patalganga plant received zero observation from USFDA earlier
Approval for generic Semaglutide Injection strengthens CDMO partnership, enabling scalable supply from OneSource’s US FDA-approved Bengaluru facility
After Phase 3 results show major hair regrowth gains
The submission is backed by positive results from the Phase 3 AFFIRM study
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Gilenya Capsules, 0.5 mg of Novartis Pharmaceuticals Corporation (Novartis)
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
Approval for Albuterol Sulfate inhalation aerosol enables Cipla Limited to enter the $1.5 billion U.S. albuterol market
Subscribe To Our Newsletter & Stay Updated